NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Latest Information Update: 10 Jan 2025
Price :
$35 *
At a glance
- Drugs Ensartinib (Primary) ; Erdafitinib (Primary) ; Larotrectinib (Primary) ; Larotrectinib (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Samotolisib (Primary) ; Selpercatinib (Primary) ; Selumetinib (Primary) ; Tazemetostat (Primary) ; Tipifarnib (Primary) ; Tipifarnib (Primary) ; Ulixertinib (Primary) ; Vemurafenib (Primary)
- Indications CNS cancer; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Glioma; Hepatoblastoma; Langerhans cell histiocytosis; Lymphoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 08 Jan 2025 Planned End Date changed from 30 Sep 2027 to 30 Jun 2025.
- 08 Jan 2025 Planned primary completion date changed from 30 Sep 2027 to 30 Jun 2025.
- 27 Dec 2024 Status changed from recruiting to active, no longer recruiting.